Piper Jaffray Cut Price Target on F5 Networks (FFIV) Following 1Q Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Citi Upgrades F5 Networks (FFIV) to Neutral
January 21, 2016 7:11 AM ESTCiti upgraded F5 Networks (NASDAQ: FFIV) from Sell to Neutral.
For an analyst ratings summary and ratings history on F5 Networks click here. For more ratings news on F5 Networks click here.
Shares of F5 Networks closed at $90.02 yesterday.
... MoreBMO Capital Remains Sidelined After F5 Networks (FFIV) Reports 1Q Beat
January 21, 2016 7:04 AM ESTBMO Capital maintained a Market Perform rating on F5 Networks (NASDAQ: FFIV), and cut the price target to $93.00 (from $108.00), following the company's 1Q earnings report. Revenues and EPS of $489M and $1.73, came in above consensus estimates of $486M and $1.60. However, BMO remains concerned that the weak product sales could last longer than expected as new network architectures may be muting demand and... More
After-Hours Stock Movers 01/20: (ECYT) (XLNX) (FEYE) Higher; (OGXI) (SLM) (SRPT) Lower (more...)
January 20, 2016 5:51 PM ESTOncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) 41.8% LOWER; announced that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. A potential PFS benefit was observed in patients with high baseline serum Hsp27 status when treated with apatorsen. The study is ongoing and overall survival results are expected in the second half of 2016.
Endocyte, Inc. (NASDAQ:... More
F5 Networks (FFIV) Tops Q1 EPS by 13c; Issues Light Q2 Outlook
January 20, 2016 4:06 PM ESTF5 Networks (NASDAQ: FFIV) reported Q1 EPS of $1.73, $0.13 better than the analyst estimate of $1.60. Revenue for the quarter came in at $489.5 million versus the consensus estimate of $485.51 million.
GUIDANCE:
F5 Networks sees Q2 2016 EPS of $1.61-$1.64, versus the consensus of... More
Trading Radar for 1/20: Goldman Sachs (GS), F5 Networks (FFIV), Sallie Mae (SLM), Brinker (EAT) Report
January 19, 2016 2:10 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
7:00am EST
8:30am EST
CPI - Street sees 0.0%Core CPI - Street sees 0.2%Housing Starts - Street sees 1.197MBUilding Permits - Street sees... More
